University of Crete (UOC)
Μελέτη των κυκλινών και των αναστολέων των κυκλινών εξαρτώμενων κινασών ως βιοδείκτες για την πρόγνωση σε ασθενείς με μελάνωμα του δέρματος
Abstract
dc:descriptionThe increasing incidence of cutaneous melanoma (CM) worldwide, combined with the observed higher mortality risk compared with other skin cancers, render the accurate diagnosis, prognosis and treatment of this malignancy of outmost importance. A variety of genetic and environmental factors have been incriminated for the malignant transformation of melanocytes, but, despite the novel advances in molecular analysis, genomics and cancer biology technologies, we are far away from completely elucidating the molecular mechanisms, responsible for inhibition of apoptosis and tumor suppressor inactivation, which lead to pathogenesis and progression of CM. As a consequence, CM still remains an unpredictable disease, and the accuracy of the traditional melanoma staging system appears not sufficient in predicting patients’ individual risk of disease recurrence and mortality. More precisely, patients suffering from locoregional melanoma of the same stage may present a totally different disease course and suboptimal adjuvant treatment may be offered. Thus, it is extremely important to develop additional prognostic tools in order to achieve optimal stratification of patients into risk subgroups and for earlier identification of individuals at high risk for recurrence. Through that process, personalized treatment of patients with CM could be offered, resulting in improved outcomes by treating more effectively high risk patients, providing less unnecessary adjuvant treatments in low risk patients and, hence, potentially diminishing healthcare costs. Cyclins and cyclin-dependent kinase inhibitors, which are key players in the cell cycle regulation, have attracted great interest in the field of melanomagenesis. Herein, it is important to examine their expression and prognostic value. The goals of this study were to investigate the expression of Cyclin D1, Cyclin E, p16, p21 and p27 in primary invasive CM, to assess their correlation with clinicopathological variables and to evaluate their potential role as prognostic biomarkers. The expression of proteins was assessed using immunohistochemistry in the primary tumors of 59 consecutive patients diagnosed with locoregional CM after diagnostic excisional biopsy and when indicated sentinel node biopsy or lymph node dissection. The population of the study was selected using certain criteria from a newly constructed database containing all melanoma patients treated in the Department of Surgical Oncology of the University Hospital of Heraklion from 2000 up to date. Patients with distant metastases at diagnosis, those with a follow-up period of less than five years and those referred with a diagnostic biopsy performed elsewhere were not included in the study. Subsequently, wide local excision, sentinel lymph node biopsy and/or regional lymph node dissection and adjuvant treatment were applied according to the international guidelines. The immunostaining of sections was analyzed using a semiquantitative process based on proportion of tumor cells showing unequivocal positive reaction. In the cases of Cyclin D1, p21 and p27 only nuclear staining was reported. To the contrary, nuclear and cytoplasmic staining was graded separately for p16 and Cyclin E. The reproducibility of the process was guaranteed by defining clear cut-off criteria for each marker based on the endogenous expression of proteins in non-tumoral cells. The analysis of our data revealed positive association between the concentration of Cyclin E in nucleus and tumor thickness (p=0.017). An opposite pattern of interaction was found for p16. The level of nuclear p16 expression was inversely proportional with Breslow thickness (p=0.001) and ulceration (p=0.035), whereas low expression of p16 in the cytoplasm was only associated with thicker melanoma (p=0.004). Beyond the relationship with certain clinicopathological variables, the high expression of Cyclin E in nucleus and the loss of p16 in cytoplasm and nucleus were associated with shorter overall survival (p<0.001, p=0.012 and p=0.002, respectively). Similarly, shorter relapse free survival was significantly related to absence of p16 from cytoplasm and nucleus (p=0.011 and p=0.002, respectively), and elevated expression of Cyclin E in nucleus (p<0.001). Interestingly, Cyclin E proved to be a prognostic factor for survival parameters, as strong as Breslow thickness, which is known as the strongest prognostic factor in clinically localized CM. Larger studies should confirm the definite prognostic value of p16 and Cyclin E in CM and assess whether indeed Cyclin E might be a prognostic biomarker even stronger than Breslow thickness. Moreover, subgroup analysis in larger cohorts should assess the prognostic value of p16 and Cyclin E in various invasive depths and nodal stages, allowing for more optimal risk stratification than the current TNM system, and subsequently for optimal adjuvant treatment. Beyond assessing the prognostic roles of these cell cycle regulators individually, these biomarkers that identify more aggressive disease may also be useful as targets for precision medicine in the future.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkionis, Ioannis
- Γκιώνης, Ιωάννης
Subjects
dc:subject × 24- Μελάνωμα δέρματος
- Κυκλίνη D1
- Κυκλίνη Ε
- Πρωτείνη p16
- P21 πρωτεϊνη
- Πρωτεΐνη p27
- Ανοσοϊστοχημεία
- Επιβίωση ασθενών
- Πρόγνωση
- Cutaneous melanoma
- Cyclin D1
- Cyclin E
- Protein p16
- P21 protein
- p27 protein
- Immunohistochemistry ( IHC)
- Patients' survival
- Prognosis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Χειρουργική
- Clinical Medicine
- Medical and Health Sciences
- Surgery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59357